Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive KarXT for inadequately controlled schizophrenia
jRCT2041240126Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Adjunctive KarXT with Adjunctive placebo (2 arms). Primary endpoint: Change from baseline in Positive and Negative Syndrome Scale total score at Week 6. Started Dec 2024; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2041240126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240126.